Pharmaceutical and Biologics Litigation
Overview
Crowell & Moring is home to a team of patent litigators representing and advising clients in cases arising under the “Hatch-Waxman Act” and the Biologics Price Competition and Innovation Act (BPCIA). Our life sciences patent litigation group currently consists of more than 10 intellectual property litigators who bring experience, dedication, and skill to life sciences patent litigation.
Contacts
Insights
Client Alert | 5 min read | 07.01.26
What U.S. Patent Holders Need to Know About Inequitable Conduct Right Now
If a court finds that a patent applicant intentionally misrepresented or withheld material information from the USPTO with the intent to deceive, the consequences are severe, leading to unenforceability of the entire patent (and likely any later patents claiming priority to the unenforceable patent).
Firm News | 7 min read | 06.04.26
Client Alert | 3 min read | 05.21.26
Judge Jennifer Choe-Groves Takes Over Several DNJ Hatch-Waxman Cases
Client Alert | 3 min read | 05.18.26
“To IPR or Not to IPR?” — Director Squires Offers Clarity, With Data and History
Insights
Patent Cases – An Open Door for MOT Patent Litigation
|01.12.22
Crowell & Moring's Litigation Forecast 2022
- |
09.18.15
Bloomberg BNA Pharmaceutical Law & Industry Report
Professionals
Insights
Client Alert | 5 min read | 07.01.26
What U.S. Patent Holders Need to Know About Inequitable Conduct Right Now
If a court finds that a patent applicant intentionally misrepresented or withheld material information from the USPTO with the intent to deceive, the consequences are severe, leading to unenforceability of the entire patent (and likely any later patents claiming priority to the unenforceable patent).
Firm News | 7 min read | 06.04.26
Client Alert | 3 min read | 05.21.26
Judge Jennifer Choe-Groves Takes Over Several DNJ Hatch-Waxman Cases
Client Alert | 3 min read | 05.18.26
“To IPR or Not to IPR?” — Director Squires Offers Clarity, With Data and History














